keyword
MENU ▼
Read by QxMD icon Read
search

Prostate cancer survival

keyword
https://www.readbyqxmd.com/read/28239558/role-of-androgen-receptor-splice-variants-in-prostate-cancer-metastasis
#1
Jin Xu, Yun Qiu
Prostate cancer (PCa) is one of the most lethal cancers in western countries. Androgen receptor (AR) signaling pathway plays a key role in PCa progression. Despite the initial effectiveness of androgen deprivation therapy (ADT) for treatment of patients with advanced PCa, most of them will develop resistance to ADT and progress to metastatic castration resistant prostate cancer (mCRPC). Constitutively transcriptional activated AR splice variants (AR-Vs) have emerged as critical players in the development and progression of mCRPC...
October 2016: Asian J Urol
https://www.readbyqxmd.com/read/28239006/cancer-treatment-delays-in-american-indians-and-alaska-natives-enrolled-in-medicare
#2
Scott V Adams, Aasthaa Bansal, Andrea N Burnett-Hartman, Stacey A Cohen, Andrew Karnopp, Victoria Warren-Mears, Scott D Ramsey
To assess whether timing of initial post-diagnosis cancer care differs between American Indian and Alaska Native (AI/AN) and non-Hispanic White (NHW) patients, we accessed SEER-Medicare data for breast, colorectal, lung, and prostate cancers (2001-2007). Medicare claims data were examined for initiation of cancer-directed treatment. Overall, AI/ANs experienced longer median times to starting treatment than NHWs (45 and 39 days, p < .001) and lower rates of treatment initiation (HR[95%CI]: 0.86[0.79-0.93])...
2017: Journal of Health Care for the Poor and Underserved
https://www.readbyqxmd.com/read/28238343/indication-for-early-cystectomy-in-nonmuscle-invasive-bladder-cancer-literature-review
#3
L Cogorno Wasylkowski, E Ríos-González, E Linares Espinós, A Leibar Tamayo, L Martínez-Piñeiro Lorenzo
CONTEXT: High-risk nonmuscle-invasive bladder cancer is a disease that includes a heterogeneous group of patients, for whom close follow-up is recommended due to the risk of progression to a muscle-invasive tumour. The treatment of choice for these tumours is transurethral resection of the bladder tumour followed by a programme of bacillus Calmette-Guerin instillations. There is a subgroup of patients who have a greater risk of progression and who benefit from early radical treatment...
February 18, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28238148/long-term-cancer-control-outcomes-of-robot-assisted-radical-prostatectomy-for-prostate-cancer-treatment-a-meta-analysis
#4
Lei Wang, Baojun Wang, Qing Ai, Yu Zhang, Xiangjun Lv, Hongzhao Li, Xin Ma, Xu Zhang
PURPOSE: Robot-assisted radical prostatectomy (RARP) provides significant advantages in short-term oncological outcomes for prostate cancer patients. However, data regarding the long-term cancer control outcomes of RARP are limited and inconsistent. This study aimed to evaluate these long-term outcomes. METHODS: Medline, Scopus, and other databases were searched for studies published from January 2010 to July 2016. Case series and prospective cohort studies on the long-term cancer control outcomes of patients who underwent RARP were subjected to meta-analyses by using the R statistical software...
February 25, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28237181/moderate-hypofractionated-postprostatectomy-volumetric-modulated-arc-therapy-with-daily-image-guidance-vmat-igrt-a%C3%A2-mono-institutional-report-on-feasibility-and-acute-toxicity
#5
Sergio Fersino, Umberto Tebano, Rosario Mazzola, Niccolò Giaj-Levra, Francesco Ricchetti, Gioacchino Di Paola, Alba Fiorentino, Gianluisa Sicignano, Stefania Naccarato, Ruggero Ruggieri, Stefano Cavalleri, Filippo Alongi
INTRODUCTION: The aim of this study was to evaluate the acute toxicity profiles of a moderate hypofractionated regimen with volumetric modulated arc therapy (VMAT) in patients with prostate cancer (PC) who underwent radical prostatectomy. MATERIAL AND METHODS: From December 2012 to February 2016, 125 patients, previously having undergone radical prostatectomy, received adjuvant (64 patients) or salvage (61 patients) radiotherapy (RT) inside an institutional protocol of moderate hypofractionation schedule using the VMAT technique (Varian RapidArc, Palo Alto, CA)...
February 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28235401/expression-of-socs1-and-the-downstream-targets-of-its-putative-tumor-suppressor-functions-in-prostate-cancer
#6
Martin Chevrier, Diwakar Bobbala, Alberto Villalobos-Hernandez, Md Gulam Musawwir Khan, Sheela Ramanathan, Caroline Saucier, Gerardo Ferbeyre, Sameh Geha, Subburaj Ilangumaran
BACKGROUND: Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa), elevated expression of miR-30d that targets SOCS1 mRNA is associated with increased risk of disease recurrence. SOCS1 can mediate its tumor suppressor functions by diverse mechanisms such as inhibiting the JAK-STAT signaling pathway, promoting the tumor suppressor functions of p53, attenuating MET receptor tyrosine kinase signaling and blocking the oncogenic potential of the cell cycle inhibitor p21(CIP1) (p21)...
February 24, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28230277/immune-checkpoint-blockade-biology-in-mouse-models-of-glioblastoma
#7
Alan T Yeo, Al Charest
Glioblastoma Multiforme (GBM) is a highly malignant primary brain cancer that is associated with abysmal prognosis. The median survival of GBM patients is ∼15 months and there have not been any significant advance in therapies in over a decade, leaving treatment options limited. There is clearly an unmet need for GBM treatment. Immunotherapies are treatments based on usurping the power of the host's immune system to recognize and eliminate cancer cells. They have recently proven to be a successful strategy for combating a variety of cancers...
February 23, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28230260/elevation-of-sharpin-protein-levels-in-prostate-adenocarcinomas-promotes-metastasis-and-impairs-patient-survivals
#8
Hai Huang, Tao Du, Yiming Zhang, Yiming Lai, Kaiwen Li, Xinxing Fan, Dingjun Zhu, Tianxin Lin, Kewei Xu, Jian Huang, Leyuan Liu, Zhenghui Guo
BACKGROUND: SHARPIN, SHANK-associated RH domain interacting protein, associates with a linear ubiquitin chain assembly complex (LUBAC) to regulate inflammation and immunity. It has been reported that SHARPIN is highly expressed in several human tumors including ovarian cancer and liver cancer. We found that SHARPIN is also highly expressed in prostate cancer cell lines of DU145, LNCAP, and PC-3. Suppression of SHARPIN caused an inhibition of NF-κB signal and decreases in tumorigenesis of cultured cells in NOD/SCID mouse model...
February 23, 2017: Prostate
https://www.readbyqxmd.com/read/28230003/risk-stratification-for-disease-progression-in-pt3-prostate-cancer-after-robot-assisted-radical-prostatectomy
#9
Jeong Hee Hong, Young Suk Kwon, Isaac Yi Kim
The aim of this study is to identify optimal patients for adjuvant radiation therapy (ART) in pT3 prostate cancer. The role of ART for patients with adverse pathologic features after radical prostatectomy (RP) has been demonstrated, but over- or under-treatment remains a significant concern. Two-hundred and five patients with pT3N0M0 who underwent robot-assisted RP without ART were analyzed. Multivariate Cox proportional regression analyses were used to identify predictors of biochemical recurrence (BCR) and clinical progression (CP)...
February 21, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28229393/mechanisms-of-therapeutic-resistance-in-prostate-cancer
#10
REVIEW
Mary Nakazawa, Channing Paller, Natasha Kyprianou
Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in managing castration-resistant prostate cancer (CRPC) stems not from the lack of therapeutic options but from the limited duration of clinical and survival benefit offered by treatments in this setting due to primary and acquired resistance. The remarkable molecular heterogeneity and tumor adaptability in advanced prostate cancer necessitate optimization of such treatment strategies. While the future of CRPC management will involve newer targeted therapies in deliberately biomarker-selected patients, interventions using current approaches may exhibit improved clinical benefit if employed in the context of optimal sequencing and combinations...
February 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28228781/denosumab-is-really-effective-in-the-treatment-of-osteoporosis-secondary-to-hypogonadism-in-prostate-carcinoma-patients-a-prospective-randomized-multicenter-international-study
#11
Carlo Doria, Paolo Tranquilli Leali, Federico Solla, Gianluca Maestretti, Massimo Balsano, Robero Mario Scarpa
INTRODUCTION: Osteoporosis is a complication of androgen deprivation therapy (ADT) in men with prostate carcinoma. The best defense against osteoporosis in prostate cancer is to identify patients with a high risk for fracture during the first clinical visit, select an effective anti-osteoporosis agent, and advise the patient to change his lifestyle and diet to prevent further bone loss. New agents include denosumab, a human monoclonal antibody that inhibits the RANK ligand (RANKL). RANKL promotes the formation, activity, and survival of osteoclasts and, thus, supports the breakdown of bone...
September 2016: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28227780/impact-of-prostate-biopsy-tumor-amount-on-imaging-based-prognostics-employing-transductive-semi-supervised-regression
#12
Faisal M Khan, Casimir A Kulikowski, Faisal M Khan, Casimir A Kulikowski, Casimir A Kulikowski, Faisal M Khan
For newly diagnosed prostate cancer patients with a positive biopsy, there are a variety of treatment options to consider. To aid physicians and patients in their decision making, a variety of predictive assays have emerged within the last decade, many of them imaging based. These assays build predictive models for survival analysis to provide personalized risk assessments for the patients. However, there have rarely been any published studies on how the amount of tumor in the positive prostate biopsy affects the predictive power of these imaging based assays...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28225445/adjuvant-radiotherapy-versus-wait-and-see-strategy-for-pathologic-t3-or-margin-positive-prostate-cancer-a-meta-analysis
#13
M Parvez Shaikh, Fiori Alite, Meng-Jia Wu, Abhishek A Solanki, Matthew M Harkenrider
OBJECTIVE: To conduct a meta-analysis of the randomized controlled trials (RCTs) comparing adjuvant radiotherapy (ART) to wait-and-see (WS) strategy in pathologic T3 or margin-positive prostate cancer. METHODS: A comprehensive EMBASE, MEDLINE, http://www.clinicaltrails.gov, and Cochrane Library search for RCTs of ART versus WS was done. Results were synthesized for metastasis-free, biochemical progression-free, clinical progression-free, hormone-free, and overall survival as well as gastrointestinal (GI) and genitourinary (GU) toxicities...
February 20, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28224113/intensity-modulated-radiation-therapy-with-stereotactic-body-radiation-therapy-boost-for-unfavorable-prostate-cancer-a-report-on-3-year-toxicity
#14
Ima Paydar, Abigail Pepin, Robyn A Cyr, Joseph King, Thomas M Yung, Elizabeth G Bullock, Siyuan Lei, Andrew Satinsky, K William Harter, Simeng Suy, Anatoly Dritschilo, John H Lynch, Thomas P Kole, Sean P Collins
BACKGROUND: Recent data suggest that intensity-modulated radiation therapy (IMRT) plus brachytherapy boost for unfavorable prostate cancer provides improved biochemical relapse-free survival over IMRT alone. Stereotactic body radiation therapy (SBRT) may be a less invasive alternative to brachytherapy boost. Here, we report the 3-year gastrointestinal (GI) and genitourinary (GU) toxicities of IMRT plus SBRT boost. MATERIALS AND METHODS: Between March 2008 and September 2012, patients with prostate cancer were treated with robotic SBRT (19...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28223547/cabozantinib-targets-bone-microenvironment-modulating-human-osteoclast-and-osteoblast-functions
#15
Marco Fioramonti, Daniele Santini, Michele Iuliani, Giulia Ribelli, Paolo Manca, Nicola Papapietro, Filippo Spiezia, Bruno Vincenzi, Vincenzo Denaro, Antonio Russo, Giuseppe Tonini, Francesco Pantano
Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effect of cabozantinib on bone microenvironment using a total human model of primary osteoclasts and osteoblasts.Osteoclasts were differentiated from monocytes isolated from healthy donors; osteoblasts were derived from human mesenchymal stem cells obtained from bone fragments of orthopedic surgery patients...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28223545/ring-finger-protein-6-promotes-breast-cancer-cell-proliferation-by-stabilizing-estrogen-receptor-alpha
#16
Yuanying Zeng, Xin Xu, Siyu Wang, Zubin Zhang, Yan Liu, Kunkun Han, Biyin Cao, Xinliang Mao
Ring finger protein 6 (RNF6) is a key oncogene in both prostate cancer and leukemia, but its role is elusive in breast cancer. In the present study, we found that RNF6 was overexpressed in more than 70% of breast cancer tissues and it was associated with overall survival. RNF6 increased breast cancer cell proliferation, migration and reduced cell sensitivity to doxorubicin. Further studies showed that RNF6 was closely associated with increased expression of estrogen receptor, a critical factor in the development of breast cancers...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28223140/reduced-cell-viability-and-apoptosis-induction-in-human-thyroid-carcinoma-and-mesothelioma-cells-exposed-to-cidofovir
#17
Simona Catalani, Francesco Palma, Serafina Battistelli, Barbara Nuvoli, Rossella Galati, Serena Benedetti
Besides its well-recognized antiviral activity, Cidofovir (CDV) has been shown to exert anticancer properties both within in vitro and in vivo models. The aim of this study was to evaluate the effects of CDV on still unexplored cultured cancer cells from human mesothelioma as well as breast, colon, liver, lung, prostate, and thyroid carcinomas. Overall, a dose- and time-dependent inhibition of cell viability was observed after CDV exposure. To clarify the mechanisms underlying CDV action, apoptotic cell death was investigated in two infected cell lines [Ist-Mes1 and Ist-Mes2 mesothelioma cells (SV40+)] and in two uninfected cell lines (NCI-H2425 mesothelioma cells and FTC-133 thyroid cancer cells), which resulted the most sensitive to CDV treatment...
February 18, 2017: Toxicology in Vitro: An International Journal Published in Association with BIBRA
https://www.readbyqxmd.com/read/28222995/acute-and-late-toxicity-in-high-risk-prostate-cancer-patients-treated-with-androgen-suppression-and-hypofractionated-pelvic-radiation-therapy
#18
Sergio Faria, Russel Ruo, Fabio Cury, Marie Duclos, Luis Souhami
PURPOSE: To report acute and late toxicity rates in patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and moderate hypofractionated radiation therapy (HypoRT) to the prostate and nodal areas. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer were treated with a HypoRT regimen of 60 Gy in 20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated RT with a simultaneous integrated boost technique...
January 20, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28222973/nationwide-multi-institutional-retrospective-analysis-of-high-dose-rate-brachytherapy-combined-with-external-beam-radiotherapy-for-localized-prostate-cancer-an-asian-prostate-hdr-bt-consortium
#19
Hiromichi Ishiyama, Nobuhiko Kamitani, Hidemasa Kawamura, Shingo Kato, Manabu Aoki, Shinji Kariya, Taisei Matsumura, Motoki Kaidu, Ken Yoshida, Yaichiro Hashimoto, Yasutaka Noda, Keith H C Lim, Takatsugu Kawase, Takeo Takahashi, Koji Inaba, Motoyasu Kumano, Nobuhiko Yoshikawa, Yasuo Yoshioka, Katsumasa Nakamura, Junichi Hiratsuka, Jun Itami, Kazushige Hayakawa
PURPOSE: To report outcomes and risk factors of high-dose-rate (HDR) brachytherapy combined with external beam radiotherapy with or without androgen deprivation therapy (ADT) in prostate cancer patients. MATERIALS AND METHODS: This multi-institutional retrospective analysis comprised 3424 patients with localized prostate cancer at 16 Asian hospitals. One-thirds (27.7%) of patients received only neoadjuvant ADT, whereas almost half (49.5%) of patients received both neoadjuvant and adjuvant ADT...
February 17, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28222672/long-leukocyte-telomere-length-in-prostate-cancer-patients-at-diagnosis-is-associated-with-poor-metastasis-free-and-cancer-specific-survival
#20
Ulrika Svenson, Göran Roos, Pernilla Wikström
Previous studies have suggested that leukocyte telomere length is associated with risk of developing prostate cancer. Investigations of leukocyte telomere length as a prognostic factor in prostate cancer are, however, lacking. In this study, leukocyte telomere length was investigated both as a risk marker, comparing control subjects and patient risk groups (based on serum levels of prostate-specific antigen, tumor differentiation, and tumor stage), and as a prognostic marker for metastasis-free and cancer-specific survival...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
keyword
keyword
8536
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"